Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Percutaneous Patent Foramen Ovale Closure, No Intervention.
- Who it may be relevant to
- Registry conditions: Migraine Disorders, Patent Foramen Ovale, Right-to-Left Shunt, Cardiac. Basic parameters: 18 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Impact of Percutaneous Patent Foramen Ovale Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine
Overview
Patent Foramen Ovale (PFO) is a common congenital heart defect. Recent studies have suggested a potential association between PFO and migraines, particularly migraine with aura. It is hypothesized that PFO may allow microemboli or vasoactive substances from venous blood to bypass pulmonary metabolism and enter the arterial system directly, potentially triggering migraines. Although PFO closure has been shown to reduce the frequency and severity of migraine attacks, its long-term efficacy and underlying mechanisms require further investigation. This study aims to explore the characteristics of glymphatic system function in PFO patients and its relationship with migraine symptoms, as well as the impact of PFO closure on glymphatic function and its role in alleviating migraine symptoms. A case-control and self-controlled before-after study design is adopted. Two groups of participants are enrolled: a case group consisting of PFO patients with significant right-to-left shunt and migraine, and a control group comprising PFO patients with significant shunt but without migraine. According to clinical guidelines and after obtaining informed consent, eligible patients in the case group undergo percutaneous PFO closure. By comparing migraine symptoms and glymphatic function indicators both before and after the procedure between the two groups, the interventional effect of PFO closure and its potential mechanism will be investigated. The primary endpoint is the improvement in migraine symptoms, while the secondary endpoints include glymphatic function metrics. The findings of this study will provide new theoretical insights and clinical guidance for the management of PFO-related migraines.
Interventions
- Device Percutaneous Patent Foramen Ovale Closure
Percutaneous transcatheter closure of patent foramen ovale (PFO) is a minimally invasive procedure. Under local anesthesia, a closure device is delivered via a catheter through the femoral vein to the heart to seal the PFO tunnel. The procedure is performed under fluoroscopic and echocardiographic guidance. This intervention aims to eliminate right-to-left shunt, which is hypothesized to improve migraine symptoms and glymphatic function. - Other No Intervention
This arm does not receive the PFO closure procedure. Patients in this control group are observed under their standard care regimen without any study-specific intervention.
Primary outcome measures
- Monthly Migraine Days (MMD) [Time frame: For the intervention arm, this is 6 months post-procedure. For the control arm, this is 6 months post-enrollment.]
Secondary outcome measures (2)
- Migraine Pain Intensity (VAS Score) [Time frame: The pain intensity of migraine attacks as measured by the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst pain imaginable). The change in VAS score from baseline to the 6-month timepoint will be calculated. A negative change indicates]
- DTI-ALPS Index [Time frame: For the intervention arm, this is 6 months post-procedure. For the control arm, this is 6 months post-enrollment.]
Eligibility criteria
Inclusion criteria
- Adults aged 18 to 60 years.
- Diagnosed with patent foramen ovale (PFO) with significant right-to-left shunt.
- For the case group: Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders (ICHD-3).
- For the control group: No history of migraine.
- Willing and able to provide written informed consent.
- Education level of primary school or higher.
Exclusion criteria
- Patients with a history of PFO closure or other migraine-related surgical treatments;
- Patients with other severe cardiac or neurological diseases, mental disorders, or psychological conditions;
- Patients with contraindications to closure surgery or MRI scans (e.g., severe infection, coagulation dysfunction, cardiac pacemakers, aneurysm clips, metallic foreign bodies in the eye, non-removable metal dentures, etc.);
- Patients unable to complete migraine symptom assessments or imaging examinations due to other reasons.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 2 centers
- Luoyang Central Hospital — Luoyang
- The Second Hospital of Tianjin Medical University — Tianjin
Identifiers
NCT: NCT07170176 · XJTUIAF2025LSYY-609